Tirbanibulin (Klisyri®) is a first-in-class Src kinase signaling inhibitor and 
tubulin polymerisation inhibitor being developed by Athenex in conjunction with 
global partners for the topical treatment of actinic keratosis, and psoriasis. 
Based on the data from two pivotal phase III trials the drug was recently 
approved for marketing in the US as a topical treatment for actinic keratosis. 
This article summarizes the milestones in the development of tirbanibulin 
leading to this first approval.